3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
3
Breast Neoplasms
3
Lymphoma, Non-Hodgkin
2
Leukemia
2
Triple Negative Breast Neoplasms
1
Teratoma
1
Rhabdomyosarcoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, AIDS-Related
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Infiltrating Bladder Urothelial Carcinoma
1
Glioma
1
Choriocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Embryonal
1
Burkitt Lymphoma
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
Gemcitabine
29
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
17
Specimen Handling
16
Mitomycin
10
enfortumab vedotin
9
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
pegfilgrastim
×
90 days
×
Clear all
No trials found.